1 / 17

The Global Antibiotic Resistance Partnership

The Global Antibiotic Resistance Partnership . Global Health Council Conference Tuesday 14 June 2011 Hellen Gelband CDDEP. The Global Antibiotic Resistance Partnership--GARP.

elaina
Download Presentation

The Global Antibiotic Resistance Partnership

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Global Antibiotic Resistance Partnership Global Health Council Conference Tuesday 14 June 2011 HellenGelband CDDEP

  2. The Global Antibiotic Resistance Partnership--GARP The Global Antibiotic Resistance Partnership (GARP) aims to address the challenge of antibiotic resistance by developing actionable policy proposals in four low- and middle-income countries: India, Kenya, South Africa and Vietnam

  3. Why GARP? • Antibiotic resistance has been defined by high-income countries. Why it matters: • Access • Cost • Action takes place at the country level • Local knowledge • Locally-generated research • Sustainability

  4. Key Elements • CDDEP organization • International Advisory Group • Working Groups in each country • Affiliations with premier medical and research organizations • Coordinators +/- • All sectors represented (human/animal, public/private sectors; urban/rural)

  5. International Advisory Group--IAG Keith Klugman, Emory University, Atlanta, Chair ZulfiqarBhutta, Aga Khan University, Karachi Adriano Duse, University of the Witwatersrand, Chair, GARP-South Africa NWG NK Ganguly, National Institute of Immunology, New Delhi, Chair, GARP-India NWG David Heymann, Health Protection Agency, London Dean Jamison, University of Washington Samuel Kariuki, Kenya Medical Research Institute, Chair, GARP-Kenya NWG Nguyen Van Kinh, National Institute of Infectious and Tropical Diseases, Hanoi, Chair, GARP-Vietnam NWG Eric Simoes, University of Colorado

  6. International Advisory Group--IAG Keith Klugman, Emory University, Atlanta, Chair ZulfiqarBhutta, Aga Khan University, Karachi Adriano Duse, University of the Witwatersrand, Chair, GARP-South Africa NWG NK Ganguly, National Institute of Immunology, New Delhi, Chair, GARP-India NWG David Heymann, Health Protection Agency, London Dean Jamison, University of Washington Samuel Kariuki, Kenya Medical Research Institute, Chair, GARP-Kenya NWG Nguyen Van Kinh, National Institute of Infectious and Tropical Diseases, Hanoi, Chair, GARP-Vietnam NWG Eric Simoes, University of Colorado

  7. Country-level Process

  8. Interesting and Useful Findings • In all GARP countries, sufficient data can be found to support high levels of antibiotic resistance, at least in some places • No GARP country has a functioning surveillance system to monitor trends • Information on antibiotic use in animals is incomplete • Most studies concentrate on urban areas and hospitals

  9. Policy Ideas Reducing Antibiotic Demand • Vaccines • Infection control in hospitals • Eliminating some animal use (e.g., growth promotion) Altering Antibiotic Supply • Restricting sales of advanced drugs (e.g., carbapenems in India)

  10. Evidence-Based Change in Policy and Practice: The GARP Strategy • All options identified, a small number chosen • Thorough and transparent analysis • Feasibility, cost, acceptability, etc.—specific to the country situation • Presented to the right people and organizations • Local supporting evidence, when possible The Critical Path

  11. Evidence-Based Change in Policy and Practice: The GARP Strategy [2] • Becoming a trusted source • Seizing opportunities for input • E.g., news stories about infections, antibiotic resistance, drug prices • Persistence Opportunist Path

  12. GARP Phase 2: The Next 3 Years • Deepening the relationship in the GARP founding countries • Expanding the partnership: GARP phase 2 countries • Structuring the partnership itself • Developing tools: PneuMOD, DRI • Developing a sustainable plan for the future

More Related